Neuronetics ($STIM) Stock Hub 2026: Adjusted EBITDA Turned Positive — Can the Margin Hold Through the March 2027 Covenant?

01 Q2 2026 Results: A Real Operating Inflection, With Financing Attached

Neuronetics reported a substantially stronger operating quarter than Q1 and than the prior-year period. Revenue reached $41.568 million, Greenbrook remained the growth engine, consolidated gross margin moved above 50%, operating expenses fell and adjusted EBITDA turned modestly positive. Those are not cosmetic changes: the combination of higher clinic revenue, improved revenue-cycle management and a lower cost base reduced the operating loss to $1.501 million.

02 What Changed After the Q2 Report

The investment debate has moved. Before the release, the key question was whether Greenbrook growth and expense discipline could produce a credible path toward self-funding. Q2 supplied the first convincing quarterly evidence that the operating platform can approach break-even. It did not yet prove that the common equity can reach that point without further dilution or a negotiated solution with its lender.

Greenbrook carried the quarter

Greenbrook produced $26.891 million of revenue, up 16.8% and equal to 64.7% of consolidated revenue. Neuronetics attributed the margin improvement partly to better revenue-cycle management inside the clinics. That matters because collection quality and clinic economics are more important than raw appointment growth.

NeuroStar remains the weaker side of the mix

NeuroStar revenue declined 2.7% year over year to $14.677 million. Management’s official message is that the platform has not competed to its full potential and that the company is broadening the ways customers can access the technology. The strategy may reduce friction for providers, but future quarters must show whether broader access produces durable placements, treatment-session growth and acceptable unit economics.

Cost discipline moved from promise to evidence

Operating expenses fell by $3.092 million year over year. Sales and marketing declined to $9.984 million, G&A to $11.404 million and R&D to $1.336 million. The operating loss narrowed to $1.501 million and adjusted EBITDA reached $0.254 million after adding back $0.688 million of stock compensation and $0.313 million of restructuring expense.

The quarter did not eliminate the capital question

Unrestricted cash rose from $13.214 million at March 31 to $19.197 million at June 30, even as operations and investing consumed $1.4 million in Q2. The reconciliation is financing: first-half ATM issuance contributed $7.578 million net. Common shares outstanding reached 76.193 million, up 7.199 million from December 31.

03 Inside this Stock Hub

04 Executive Summary

Neuronetics is a vertically integrated interventional mental-health company built around two businesses. NeuroStar supplies transcranial magnetic stimulation systems and earns recurring revenue from treatment activity. Greenbrook operates a national network of clinics delivering TMS and SPRAVATO. The combination gives the company both technology exposure and direct access to patients, but it also created a more complex, debt-heavy and capital-intensive equity story.

Q2 2026 was the strongest evidence so far that the integration can work economically. Total revenue rose 9.1% to $41.568 million, Greenbrook grew 16.8%, gross margin expanded by 450 basis points to 51.1% and operating expenses fell 12%. Adjusted EBITDA turned positive at $0.254 million, compared with a $5.624 million loss a year earlier. Net cash used in operations and investing fell to $1.4 million.

The improvement is meaningful, but not sufficient on its own. NeuroStar revenue fell 2.7%, first-half adjusted EBITDA remained negative $6.329 million, and first-half operating plus investing cash use totaled about $11.018 million. The company funded part of that requirement through its ATM, generating $7.578 million net. Shares outstanding rose to 76.193 million, 10.4% above year-end.

Guidance also became more credible but more nuanced. Revenue guidance narrowed from $160–166 million to $160–164 million. Gross-margin guidance increased to 48%–50%, while operating-expense guidance fell to $95–100 million. The cash-flow range improved to negative $10.5–14.5 million for operations and investing, but the measurement basis differs from the former operations-only guide and should not be treated as a perfectly like-for-like raise.

05 Why $STIM Matters Now

STIM now sits at a genuine operating inflection. In Q1, the story was dominated by cash burn and covenant risk. In Q2, the same platform generated a 51.1% gross margin, positive adjusted EBITDA and only $1.4 million of combined operating and investing cash use. That creates a more credible path toward self-funding than the market had after the first quarter.

The equity remains unusually sensitive to financing. A small change in quarterly cash use matters because unrestricted cash was $19.197 million against $61.519 million of long-term debt on the balance sheet. A small change in share issuance matters because 76.193 million shares were already outstanding at June 30, versus 68.994 million at year-end. A covenant amendment can matter more than a modest revenue beat because lender discretion affects the survival value of the common stock.

Five variables now drive the debate

• Greenbrook durability: whether clinic growth remains double digit while margins hold.
• NeuroStar recovery: whether broader access models reverse the 2.7% Q2 decline without sacrificing economics.
• Cash repeatability: whether Q3 resembles Q2 rather than the cash-heavy Q1.
• Capital discipline: whether post-June ATM issuance is limited and clearly disclosed.
• Covenant resolution: whether management obtains a durable amendment, waiver or refinancing before March 2027.

06 Company Overview: A Device Business Wrapped Around a Clinic Network

Neuronetics is a commercial-stage medical-technology and healthcare-services company based in Malvern, Pennsylvania. Its original franchise is the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation platform. The company expanded into direct patient care by acquiring Greenbrook, which operates interventional psychiatry clinics across the United States.

The combined company reports two practical economic engines:

1. NeuroStar platform economics

Neuronetics sells or places systems with physician practices and clinics. It then generates recurring revenue when those installed systems deliver treatment sessions. Additional revenue comes from service, repairs, warranties, training and other support. This model can provide higher-margin, repeat-use economics when system utilization grows.

2. Greenbrook clinic economics

The company receives patient-service revenue directly from clinics providing TMS, SPRAVATO and other mental-health services. Clinic revenue is based on net patient fees after contractual allowances and discounts. This creates more control over the patient funnel but introduces labor, facility, reimbursement, collection and lease exposure.

Q1 clinic revenue represented roughly 63% of U.S. revenue. Treatment sessions represented about 27% and systems about 9%. That mix explains why headline revenue growth can coexist with lower consolidated gross margin: services provide scale and strategic control, while product and recurring session economics can be more attractive at the gross-profit level.

07 NeuroStar TMS: Product, FDA Clearances and Reimbursement

NeuroStar delivers transcranial magnetic stimulation using pulsed magnetic fields designed to induce electrical currents in targeted brain regions. Treatment is non-systemic and non-invasive, which differentiates it from oral drugs and implanted devices. The platform is prescription-only and is used in supervised clinical settings.

FDA-cleared indications

According to Neuronetics’ SEC filings and product disclosures, NeuroStar is cleared in the United States for:

• adult patients with major depressive disorder who failed to achieve satisfactory improvement from prior antidepressant medication in the current episode;
• use as an adjunct for adults with obsessive-compulsive disorder;
• decreasing anxiety symptoms in adults with major depressive disorder and comorbid anxiety symptoms; and
• first-line adjunctive treatment of major depressive disorder in adolescents aged 15–21.

The adolescent clearance expanded the addressable population and gave NeuroStar a differentiated commercial talking point. However, a broader indication does not automatically translate into rapid procedure growth. Provider education, payer policies, patient identification, scheduling capacity and treatment adherence determine how much of a regulatory expansion becomes revenue.

Reimbursement is a genuine competitive asset

Neuronetics estimates that more than 104 major private insurers, including the 25 largest private insurers and federal healthcare programs, maintain TMS coverage policies representing more than 300 million covered lives, or roughly 95% of U.S. payer-covered lives. That is important because interventional mental-health adoption is constrained not only by clinical acceptance but also by who can authorize, supervise and bill for treatment.

In April 2026, Optum/UnitedHealthcare/United Behavioral Health expanded its clinical policy to permit psychiatric mental-health nurse practitioners to order, supervise and administer NeuroStar in jurisdictions with full practice authority. Neuronetics said the change applied across 26 states and Washington, D.C., reaching approximately 34.8 million covered lives. The practical opportunity is broader provider capacity, especially where psychiatrist availability is limited. The practical risk is that coverage policy does not guarantee utilization: clinics must still recruit eligible patients and run efficient schedules.

Clinical-data claims require context

Neuronetics promotes a very large real-world outcomes dataset. The scale can support physician confidence, payer discussions and product development. Nevertheless, registry evidence and randomized controlled evidence answer different questions. The company’s own footnotes note that registry patients were treated under real-world conditions and could have received concomitant medications or other depression treatments. These data are commercially useful, but they do not eliminate confounding variables.

Safety and treatment friction

The most common disclosed side effect is transient pain or discomfort at or near the treatment site. The company reports a rare seizure risk of less than 0.1% per patient, and NeuroStar should not be used in patients with non-removable conductive metal in or near the head. Beyond formal safety, the business must manage treatment friction: TMS generally requires repeated appointments, and patient access, transportation, scheduling and authorization can affect completion rates and clinic utilization.

Competition

Neuronetics identifies direct TMS competitors including BrainsWay, Apollo TMS, Magstim, MagVenture, CloudTMS and Nexstim. It also competes with antidepressants, esketamine, electroconvulsive therapy and emerging treatment modalities. The competitive question is not simply which device works. It includes treatment time, workflow, reimbursement support, provider economics, evidence quality, brand recognition and the ability to identify and convert patients.

Technology development and neuronavigation

In May 2026, Neuronetics announced a preferred partnership with ANT Neuro to offer the visor2 neuronavigation system alongside NeuroStar. The technology adds real-time spatial tracking and 3D visualization intended to improve targeting visibility and consistency. A broader rollout is planned for the second half of 2026. Commercial terms were not disclosed, so the collaboration remains a product enhancement with no revenue contribution that the public record can size.

At year-end 2025, Neuronetics reported 62 issued or allowed patents and 17 pending patent applications worldwide. The portfolio includes TMS technology, system design, methods, manufacturing processes and potential future products. Some patents begin expiring in 2026, but the portfolio extends into later years. As with most device businesses, commercial durability depends on more than patents: installed-base relationships, evidence, service, reimbursement and sales execution matter heavily.

08 Greenbrook: The Acquisition That Changed the Company

Neuronetics completed the Greenbrook acquisition effective December 9, 2024. Greenbrook became a wholly owned subsidiary, and its results have been included in Neuronetics’ consolidated financial statements since the closing date. The transaction transformed STIM’s reported scale and financial profile.

Before closing, Madryn converted Greenbrook debt and interim funding into Greenbrook equity. Madryn held 95.3% of Greenbrook immediately before the transaction-related exchange and emerged as Neuronetics’ largest shareholder. Neuronetics issued approximately 25.3 million common shares and paid $4.2 million in cash consideration. This history matters because the acquisition, ownership concentration, board representation and capital structure are connected.

Strategic logic

• control more of the patient journey;
• capture direct clinic revenue instead of only device and session revenue;
• cross-sell NeuroStar and SPRAVATO;
• centralize referral, call-center, marketing and reimbursement capabilities;
• create a national platform that could host additional interventional therapies.

New risks

• lower consolidated gross margin from service mix;
• clinic labor, rent and operating leverage;
• payer collection and accounts-receivable complexity;
• integration and standardized-execution risk;
• large shareholder concentration and potential share overhang.

The reported 99% revenue growth in 2025 was driven mainly by including Greenbrook for a full year. The more informative comparison is adjusted pro forma: Neuronetics reported 15% full-year pro-forma growth, while Greenbrook clinic revenue increased 28% on an adjusted pro-forma basis. Those numbers indicate that the combination was not merely an accounting illusion. The underlying platform grew, especially in clinics.

At the same time, gross margin fell to 48.5% in 2025 from 72.3% in 2024 because clinic services became a major part of the mix. This is not automatically negative: a lower-margin business can create more gross-profit dollars and strategic control. But valuation must reflect the blended model. A comparison with pure high-margin medical-device companies only holds if the recurring device and session contribution reaccelerates and clinic economics become sustainably profitable.

The May 2026 presentation listed 93 Greenbrook clinics nationwide and 84 REMS-certified treatment centers offering SPRAVATO. It also described more than 800 NeuroStar customer sites. Management’s growth plan includes referral automation, digital and direct-to-consumer targeting, standardized operations, centralized support and a broader continuum of care. These initiatives are plausible; the evidence investors need is improved appointment volumes, revenue per clinic, contribution margin and cash conversion.

Rockville Center of Excellence: strategic signal, not yet a quantified revenue catalyst

On July 28, Greenbrook opened a nearly 7,000-square-foot National Center of Excellence in Rockville, Maryland, its largest location to date. The facility is REMS-certified and designed for high-volume NeuroStar TMS and SPRAVATO operations. It will also serve as a national clinical-innovation and research site, with management describing it as a pilot location for emerging treatment modalities before potential network-wide implementation.

The strategic read-through is positive: Neuronetics is building a standardized flagship that can test workflows, patient throughput, referral conversion and new therapies. However, the company did not disclose construction cost, expected revenue, break-even timing or incremental patient capacity. The facility should therefore be treated as an execution platform and optionality asset—not automatically booked as a near-term earnings driver.

09 Q2 2026 Financial Deep Dive

Q2 was not simply better than the prior year; it was dramatically better than Q1 on revenue, margin, operating loss, EBITDA and cash use. The sequential comparison helps separate a seasonally weak opening quarter from a potentially improved operating run rate.

Revenue quality

Greenbrook supplied nearly two-thirds of Q2 revenue and all reported year-over-year consolidated growth. NeuroStar declined by $0.407 million year over year. The platform therefore still depends on clinic execution while management rebuilds the device-side commercial model.

Margin and expense quality

Gross profit increased to $21.223 million from $17.758 million while total cost of revenue was effectively unchanged at roughly $20.35 million. Operating expenses fell $3.092 million. Both levers were needed to produce the $6.557 million improvement in operating loss.

Adjusted EBITDA is useful, but not cash

Q2 adjusted EBITDA of $0.254 million adds back $0.688 million of stock compensation and $0.313 million of restructuring costs. It is a legitimate sign of operating progress, but it does not pay interest or replace working-capital needs. First-half adjusted EBITDA remained negative $6.329 million and first-half operating cash flow remained negative $10.429 million.

10 2026 Guidance and the Run-Rate Math

Second-half revenue requirement

First-half revenue was $76.022 million. Reaching the updated full-year range requires $83.978–87.978 million in the second half, or an average of $41.989–43.989 million per quarter. The low end requires only about 1.0% sequential growth from Q2; the high end requires about 5.8%.

Margin requirement

First-half gross margin was approximately 49.2%, calculated from $37.377 million of gross profit on $76.022 million of revenue. The revised 48%–50% annual range is therefore achievable if the company avoids a material reversal in clinic collections or revenue mix.

Cash-flow requirement

First-half operating and investing cash use totaled about $11.018 million. The full-year range calls for combined use of $10.5 million to $14.5 million, so the favorable end of that range has already been passed by roughly half a million dollars, and about $3.5 million of room remains against the other end for the entire second half. That is a narrow margin even after Q2’s strong result, and it makes Q3 cash disclosure one of the most important next data points.

A nearer deadline sits on the same cash. The third amendment to the credit agreement, dated August 1, 2025, lowered the minimum liquidity requirement to $2 million through September 30, 2026; past that date the original threshold applies again unless the parties amend it once more. The second-quarter Form 10-Q states that the company was in compliance with its covenants as of June 30, 2026 and announces no extension. The March 2027 test remains the most discussed item, but it is not the first one on the calendar.

11 Cash, Debt and the Unresolved Covenant

At June 30, Neuronetics reported $19.197 million of unrestricted cash and $5.750 million of restricted cash. Restricted cash should not be treated as freely available operating liquidity. Long-term debt had a carrying value of $61.519 million, and interest expense was $2.125 million in Q2.

Why cash rose during a cash-consuming quarter

Unrestricted cash increased by $5.983 million from March 31 to June 30 even though Q2 operations and investing used $1.4 million. First-half ATM proceeds explain most of the bridge: the company raised $7.954 million gross and $7.578 million net after issuance costs.

The March 2027 issue remains central

The March 31 filing said current projections placed trailing twelve-month revenue for March 31, 2027 below the minimum covenant and warned that the company would not have the liquidity to repay the facility if the lender called it. The August 11 earnings release did not announce a covenant amendment, waiver or refinancing. Until a newer SEC filing explicitly changes that disclosure, it remains an unresolved risk rather than a closed problem.

12 Capital Structure and Dilution Risk

Common shares outstanding increased from 68.994 million at December 31, 2025 to 76.193 million at June 30, 2026, a rise of 7.199 million or approximately 10.4%. Weighted-average shares in Q2 were 73.129 million, 10.5% above the prior-year quarter.

ATM financing is not automatically destructive if it prevents a liquidity crisis and funds a transition to sustainable cash flow. The economic test is whether each dollar raised creates more than a dollar of long-term common-equity value after dilution. Q2 improved that argument, but the average price and number of shares issued under the ATM remain essential.

13 Management, Ownership and Activist Pressure

Leadership reset

Dan Reuvers became president and CEO on March 23, 2026. He brought more than three decades of medical-device experience and a mandate centered on growth, earnings and cash flow. The timing is important: he inherited a newly integrated clinic platform, a high-cost debt structure and a covenant issue disclosed weeks later.

Nir Naor became Executive Vice President, Chief Financial Officer and Treasurer on July 23. His background includes finance leadership at Axogen, Arbor Pharmaceuticals, Mölnlycke, UCB and AstraZeneca, along with investment banking, audit and legal experience. Neuronetics granted him 500,000 inducement RSUs. The August 17 Form 8-K later fixed the effective date: Naor became principal financial and accounting officer on August 12, ending Francis X. Brown III’s interim role on August 11, the day of the Q2 release, with Brown staying on as a consultant.

Cory Anderson was promoted to Executive Vice President and General Manager of Greenbrook effective July 1, while William Andrew Macan, whom the company lists as Andrew Macan, stepped down as Chief Legal Officer and Corporate Secretary on August 15. The company disclosed separation and retention payments for Macan, including vesting of 164,361 previously granted RSUs. Robert Greene had already joined as senior vice president of sales in June. The result is a broad management reset during a financially sensitive integration period.

Concentrated ownership

The 2026 proxy reported Madryn and related entities at 20.737 million shares, or 29.8%; Jorey Chernett at 9.779 million shares, or 14.1%; and Parian Ultreia at 4.885 million shares, or 7.0%. Madryn also has board representation and rights connected to its ownership. Concentrated ownership can align sophisticated capital with long-term outcomes, but it can also reduce the influence of smaller holders and create overhang if a large investor seeks liquidity.

What the register did in the second half of August

Three filings changed the picture after the proxy snapshot, and they point in opposite directions.

Chernett bought more. A Form 4 filed August 17 reports the purchase of 14,000 shares on August 14 at a weighted average of $3.16, in transactions between $3.13 and $3.17. An Amendment No. 4 to his Schedule 13D, filed August 24, puts the position at 10,602,988 shares, 13.92% of the class. The share count has risen from the 9.779 million in the proxy while the percentage has slipped, because the company issued stock faster than he accumulated it. The amendment states its purpose plainly: it was filed mainly to reflect the current ownership percentage after the change in shares outstanding reported in the Form 10-Q. The same Form 4 also reports the August 13 sale of 100 call options struck at $5 and expiring February 19, 2027, at $3.21. A footnote to that line states that the sale is a matchable transaction under Section 16(b), that the reporting person has calculated a short-swing profit on it, and that he intends to disgorge that profit to the company. The option line and that footnote belong together.

Point72 crossed 5%. A Schedule 13G filed August 14 by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen reports 3,822,124 shares, 5.0%, as of August 13, 2026. It is a passive declaration under Rule 13d-1(c) and says nothing about intent, but a new 5% holder in a company already carrying an activist 13D is a change in the composition of the register.

The departing officer sold vested stock. William A. Macan, who stepped down as chief legal officer on August 15, filed two Forms 144: 121,033 shares on August 18 for $388,273.87 and 149,891 shares on August 19 for $463,934.30. Both describe the securities as acquired through restricted stock vesting on August 14, and the first notes that the sale includes the amount needed to cover the tax obligation arising from settlement of the vested award. The second filing lists him as a former officer. Both filings describe compensation awards settling and being sold, with the first noting the tax withholding element.

Both Forms 144 report 76,197,222 shares outstanding. That is the figure on the Form 10-Q cover, stated as of August 5, 2026; the 76.193 million that appears elsewhere on this page comes from the balance sheet and is stated as of June 30. The two differ by 4,222 shares because they are counted five weeks apart.

The 2025 10-K stated that Madryn had requested registration rights that would facilitate its ability to sell shares. Registration does not mean a sale must occur, but the possibility matters for supply and governance.

Pointillist’s strategic-alternatives campaign

In April 2026, Chernett called for an immediate comprehensive review of strategic alternatives, including a potential sale of Neuronetics’ TMS business. The filing argued that the existing structure was not maximizing value and that separating or divesting the TMS business could improve financial flexibility. Neuronetics responded that it agreed the market valuation did not fully reflect the business and remained open to constructive engagement.

No formal strategic-review process or signed transaction had been announced as of August 2. A sale, separation or take-private therefore sits in the category of optionality, not confirmed catalyst. Activist pressure can accelerate value recognition, but it can also distract management, complicate lender discussions or lead to a transaction that favors one stakeholder group over another.

Insider accumulation

SEC Form 4 filings showed additional purchases by Chernett in April, May and July 2026. On July 14 he purchased 35,000 shares at a weighted-average price of $1.78, bringing his directly owned position to 10,588,988 shares. Continued buying increases his economic exposure, but it does not resolve the company’s liquidity needs or guarantee that his preferred strategic outcome will occur.

Annual-meeting signal

All directors were elected at the May 2026 annual meeting, but several nominees received substantial withheld votes. The 2026 equity incentive plan passed with approximately 23.8 million votes for, 16.7 million against and 0.8 million abstaining. This does not change corporate control, but it indicates meaningful shareholder disagreement around governance and compensation.

14 Timeline: How the Current Setup Developed

15 Bull, Base and Bear Scenarios

These scenarios organize decision variables. They are not forecasts, price targets or recommendations.

16 Advanced Operating Charts

These editorial charts reorganize reported company data. They are not company guidance and are not live market feeds.

17 Valuation: Use the Updated Share Count

The old 69.6 million share reference is no longer an adequate denominator. Using the September 1, 2026 close of $2.84, read from Marketstack, and the 76,197,222 shares reported on the cover of the Form 10-Q as of August 5 produces an illustrative basic equity value of about $216.4 million.

A low revenue multiple is not automatically cheap when debt, interest, dilution and covenant discretion sit ahead of the common equity. Conversely, an improving clinic platform can deserve a higher multiple if it demonstrates repeatable margins and self-funding. The valuation argument therefore depends more on cash conversion and capital structure than on a single sales multiple.

18 Why this Hub does not carry a price map

A Stock Hub is a document a reader comes back to months later, and a table of price bands stops being true within days of being written. The zones that used to sit here described where the stock had traded around the second-quarter release; anyone reading now would be looking at levels that no longer describe anything. What does survive is the structure underneath the price, and that is set out in the sections above: 76,197,222 shares outstanding, a float of roughly 28.88 million against insider ownership near 62%, short interest around 28% of that float, and a share count that grew 10.4% in six months through at-the-market issuance. A thin float, heavy insider ownership and a large short position together explain why this stock moves quickly on modest volume — which is a durable fact about the share register, not a level on a chart.

19 Retail Sentiment and Analyst Coverage

Stocktwits data read on August 11 showed a 45/100 neutral normalized sentiment score and a 46/100 normal current activity score. Sentiment-tagged messages were 100% bullish and 0% bearish, but that split can be based on a small, self-selected subset. The normalized score is the more useful current signal and does not support treating the feed as uniformly euphoric.

Analyst coverage remains thin

BTIG initiated coverage on July 20 with a Buy rating and a $5 target. Older visible actions included Canaccord at $3 and Piper Sandler at $3. Aggregated consensus pages showed conflicting averages before the Q2 report. With only a small analyst sample, any pre-Q2 target should be treated as a dated opinion until the analyst explicitly updates the model for 76.193 million shares, Q2 ATM activity, the new margin range and the unresolved covenant.

20 Post-Q2 Execution Checklist

21 Red Flags That Should Not Be Minimized

• Covenant risk remains unresolved: the Q1 filing projected a March 2027 revenue-covenant shortfall, and the Q2 release did not announce a solution.
• Equity financing was material: $7.578 million of first-half net ATM proceeds supported liquidity.
• Share count increased 10.4%: 76.193 million shares were outstanding at June 30.
• NeuroStar revenue declined 2.7%: Greenbrook supplied the growth while the legacy platform remained under pressure.
• Adjusted EBITDA is not free cash flow: Q2 was positive after add-backs, but first-half adjusted EBITDA was still negative $6.329 million.
• Interest remains heavy: Q2 interest expense was $2.125 million, larger than adjusted EBITDA.
• Guidance bases changed: cash-flow guidance now includes investing, and operating-expense guidance changed its stock-compensation presentation.
• Restricted cash is not unrestricted liquidity: $5.750 million of the reported $24.947 million total was restricted.

22 Bottom Line

Neuronetics delivered the quarter the operating thesis needed. Greenbrook grew 16.8%, gross margin reached 51.1%, expenses fell 12%, the operating loss narrowed to $1.501 million and adjusted EBITDA turned positive. Q2 establishes that the combined platform can approach break-even when clinic growth, collections and cost discipline work together.

The common-equity thesis is still inseparable from financing. Net ATM proceeds of $7.578 million supported first-half liquidity, shares outstanding rose to 76.193 million and long-term debt remained $61.519 million on the balance sheet. The March 2027 revenue covenant was not announced as resolved in the Q2 release.

The next step is repeatability. If Q3 sustains margins, holds cash use near the Q2 level, stabilizes NeuroStar and produces a durable lender solution, Q2 can be recognized as an operating turning point. If margins retreat and further equity is required before the covenant is addressed, the value created by Greenbrook can continue to leak away from existing holders.

Evidence confidence: high for the August 11 company financials and cash-flow statement; moderate for valuation and chart zones; unresolved for post-quarter ATM use and the final covenant path.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

23 Follow the next $STIM update

Join the Merlintrader Telegram channel for new Stock Hubs, biotech catalysts, FDA developments and small-cap market updates.